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Raised blood pressure (BP) is a major risk factor for cardiovascular disease. Previous studies have identified 47 distinct genetic variants
robustly associated with BP, but collectively these explain only a few percent of the heritability for BP phenotypes. To find additional
BP loci, we used a bespoke gene-centric array to genotype an independent discovery sample of 25,118 individuals that combined
hypertensive case-control and general population samples. We followed up four SNPs associated with BP at our p < 8.56 3 107
study-specific significance threshold and six suggestively associated SNPs in a further 59,349 individuals. We identified and replicated
a SNP at LSP1/TNNT3, a SNP at MTHFR-NPPB independent (r2 ¼ 0.33) of previous reports, and replicated SNPs at AGT and ATP2B1
reported previously. An analysis of combined discovery and follow-up data identified SNPs significantly associated with BP at p <
8.56 3 107 at four further loci (NPR3, HFE, NOS3, and SOX6). The high number of discoveries made with modest genotyping effort
can be attributed to using a large-scale yet targeted genotyping array and to the development of a weighting scheme that maximized
power when meta-analyzing results from samples ascertained with extreme phenotypes, in combination with results from nonascer-
tained or population samples. Chromatin immunoprecipitation and transcript expression data highlight potential gene regulatory
mechanisms at the MTHFR and NOS3 loci. These results provide candidates for further study to help dissect mechanisms affecting
BP and highlight the utility of studying SNPs and samples that are independent of those studied previously even when the sample
size is smaller than that in previous studies.Introduction
Raised blood pressure (BP) or hypertension [MIM 145500]
is estimated by the World Health Organization to con-
tribute 7.1 million deaths annually and is a major risk
factor for cardiovascular disease (CVD), mainly coronary
heart disease and stroke.1,2 Globally, in 2008 the preva-
lence of hypertension (defined as measured blood pressure
R140mmHg systolic BP [SBP] and/orR90mmHg diastolic
BP [DBP]) was ~40% in adults aged 25 and over.3 Candi-
date-gene and genome-wide association studies (GWAS)
for continuous BP traits in general population samples
and for case-control hypertension (HTN), have previously
identified 47 distinct genetic variants at 40 loci robustly
associated with BP and hypertension,4–15 but collectively
these explain only a few percent of the heritability for
BP phenotypes.16 To find additional BP loci, we used an
independent discovery sample of 25,118 individuals,
combining hypertensive case-control and general popula-
tion samples. We genotyped our discovery sample at42Department of Emergency and Cardiovascular Medicine, Institute of Medic
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The American49,452 SNPs by using the HumanCVD BeadChip (Illu-
mina, San Diego, CA), which is a bespoke gene-centric
array providing dense coverage of ~2,000 genes considered
a priori more likely to have functional effects on cardiovas-
cular traits, including BP.17 We tested genotypes at each
SNP for association with four continuous BP phenotypes
(SBP, DBP, mean arterial pressure [MAP] ¼ 1/3 SBP þ 2/3
DBP, and pulse pressure [PP] ¼ SBP  DBP) and also for
association with HTN and followed-up top signals in
a further 59,349 individuals by using a combination of
single SNP targeted genotyping and look-ups in pre-exist-
ing GWAS results. The five BP traits are correlated but
measure partly distinct physiological features, including
cardiac output, vascular resistance, and arterial stiff-
ness,18 and their distinct clinical and epidemiological roles
are a subject of current research. Because relatively little is
known about the genetic basis of interindividual variation
in these traits, or which traits are most powerful for detect-
ing genetic associations, we tested all five traits for associ-
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significance threshold of p < 8.56 3 107) and replicated
a SNP at LSP1/TNNT3, a SNP atMTHFR-NPPB independent
(r2 ¼ 0.33) of previous reports,4,6,11 and replicated SNPs at
ATP2B1 and AGT that were reported previously;5,12 all
were associated with at least one phenotype. In an analysis
of combined discovery and follow-up data, we found eight
genetic associations with BP, at the MTHFR-NPPB, AGT,
NPR3, HFE, NOS3, LSP1/TNNT3, SOX6, and ATP2B1 loci,
at our study-specific significance threshold of p < 8.56 3
107 for at least one phenotype. To screen for candidate
functional mechanisms, we looked for copy-number
variant tagging SNPs (CNV-tSNPs), nonsynonymous SNPs
(nsSNPs), SNPs in transcription factor binding sites identi-
fied by chromatin immunoprecipitation followed by tag
sequencing (ChIP-Seq) performed by the ENCODE consor-
tium19–24, and expressed transcript-level-associated SNPs
(eSNPs) in two independent tissue resources (a whole-
blood and tissue panel and monocytes). Our results
provide candidates for further study to help dissect mech-
anisms affecting BP and highlight the utility of studying
SNPs and samples that are independent of those studied
previously, even when the sample size is smaller than
that in previous studies.Material and Methods
Phenotyping, Genotyping, and Quality Control
Written informed consent and approval by local research ethics
committees and/or institutional review boards were obtained for
all participating studies. Cohort recruitment, sample acquisition,
BP and expression-level phenotyping, sample sizes, and demo-
graphics are described in detail in Tables S1 and S2, available
online. All analyses used data only on individuals of European
ancestry. For all of the discovery cohorts (the Allied Irish Bank
[AIBIII] study, the Anglo-Scandinavian Cardiac Outcomes Trial
[ASCOT], the BRItish Genetics of HyperTension [BRIGHT] study,
the British Womens Heart and Health Study [BWHHS], the
Genetic Regulation of Arterial Pressure of Humans In the Commu-
nity [GRAPHIC] cohort, the Malmo¨ Diet and Cancer [MDC] study,
controls from the National Blood Service [NBS], the NORdic
DILtiazem [NORDIL] trial, the PRecOcious Coronary ARtery
DISease [PROCARDIS] study, and the WhiteHall II [WHII] study),
we genotyped individuals by using the Illumina HumanCVD
BeadChip array (version 1 or version 2) and applied quality control
(QC) exclusions and checks as described in Table S3. For analyses
that combined hypertensive cases and control samples that had
been recruited or processed separately (i.e., AIBIII þ ASCOT þ
NBS, BRIGHT, and MDC þ NORDIL), there are potential stratifica-
tion artifacts that might be induced by differences in sample
handling or by DNA extraction or preparation,25 and therefore
particularly stringent QC procedures were used (Table S3).
For follow-up of top signals, individual SNPs were genotyped
with the KASPAR assay in independent samples from seven
cohorts (the British Regional Heart Study [BRHS], the Edinburgh
Artery Study [EAS], the English Longitudinal Study of Ageing
[ELSA], the HYPertension in ESTonia [HYPEST] study, the study
of the INTERplay between GENEtic susceptibility and environ-
mental factors for the risk of chronic diseases [INTERGENE], the
Medical Research Council National Survey of Health and Develop-690 The American Journal of Human Genetics 89, 688–700, Decembment [MRC NSHD] and the Northwick Park Heart Study
[NPHSII]; Table S3). In addition, for two cohorts with GWAS
data (HYPERGENES and the Ottawa Heart Genomic Study
[OHGS]) and one GWAS meta-analysis consortium (Global BPgen
[GBPG]), results were looked up (where available) for SNPs we tar-
geted for follow-up (Table S3).
The whole-blood and tissue panel eSNP data set is derived from
a combination of peripheral whole-blood samples and a tissue
panel including subcutaneous and visceral adipose tissue, liver,
and muscle. The monocyte eSNP data set is derived from mono-
cytes from 395 healthy blood donors and 363 patients with
premature myocardial infarction. For both eSNP data sets, we
measured transcript levels with whole-genome expression micro-
arrays, and we genotyped samples by using standard GWAS plat-
forms (Tables S2 and S3).Statistical Analyses
Within-Study Association Analyses
All association analyses assumed a normal linear regression model
for continuous phenotypes (DBP, MAP, PP, and SBP) and a logistic
regression model for HTN. For BP measurements from individuals
on antihypertensive or BP-lowering treatment, off-treatment
values were imputed by adding fixed constants of 15 mmHg SBP
and 10 mmHg DBP.6,26
In our analyses, we distinguished between nonascertained
studies (defined as those that selected individuals for inclusion
without reference to BP phenotypes) and ascertained studies
(defined as those that selected or enriched for individuals accord-
ing to their BP phenotype). Thus nonascertained studies include
random population samples and samples from specific demo-
graphic groups, and ascertained studies include hypertensive
case-control studies and population studies enriched for hyperten-
sive individuals). For the ascertained cohorts, HTN analyses
were performed separately with (1) ASCOT versus AIBIII þ NBS
combined, (2) BRIGHT cases versus controls, (3) NORDIL versus
MDC. Continuous BP measures were not available in the NBS
cohort and hence continuous trait analyses were performed
separately with (1) AIBIII þ ASCOT þ BRIGHT combined and (2)
MDC þ NORDIL combined in order to obtain both similar
ancestry and balance of high and low BP individuals in each asso-
ciation analyses. Genetic association tests aremore powerful when
individuals ascertained from both extremes of the phenotype
distribution are genotyped, compared with genotyping an equal
number of nonascertained (randomly sampled) individuals.27
However, both within-study association analysis, and also meta-
analysis combining nonascertained and ascertained samples,
require special analytical considerations as described below.
In studies with nonascertained samples, the joint distribution
of BP and phenotypic covariates follows a population distribution,
and therefore we included sex, age, age2 and body mass index as
covariates.6 In studies that combined ascertained samples (from
AIBIII, ASCOT, BRIGHT, MDC, NBS, and NORDIL), the various
ascertainment schemes mean that the joint distribution of BP
and phenotypic covariates is not like a population distribution.
For example, in the combined MDC and NORDIL data sets, both
SBP andHTN are negatively correlatedwith age; differential partic-
ipation in the BRIGHTstudy was female-biased, but recruitment in
the ASCOTstudy deliberately enriched for males. Therefore we did
not use phenotypic covariates in analyses of these samples,
because to do so would have biased the resulting effect-size
estimates.er 9, 2011
Asymptotic approximations that rely on large sample size and
minor allele frequency (MAF) not close to zero were used to
estimate standard errors for within-study association analyses.
An a priori decision was made not to use HTN analyses for
SNPs with MAF < 0.01. For all analyses, the goodness of asymp-
totic approximations was checked empirically by examining
quantile-quantile plots of the association test statistics after
preliminary exclusions (Figures S1–S5). For all quantitative trait
analyses, there was a clear departure from the expected uniform
distribution of p values for SNPs with MAF < 0.01 for the two
cohorts with related individuals (GRAPHIC and PROCARDIS),
and these SNPs were therefore excluded for these studies. There
was no departure from the expected distribution of p values for
ascertained studies despite their nonnormal continuous trait
distributions.
We verified independence across studies for our discovery anal-
ysis by computing robust estimates of the pairwise interstudy test
statistic correlations. For each pairwise study comparison and for
each trait in turn, we calculated the Spearman correlation between
association test statistics, by using 12,025 SNPs for continuous
traits and 11,832 SNPs for HTN, obtained by pruning SNPs in
strong linkage disequilibrium (LD) with other SNPs and excluding
SNPs where study results failed QC. Themaximum correlation (for
all pairs and all phenotypes) was r ¼ 0.038 (for AIBIII þ ASCOT þ
BRIGHT versus BWHHS for MAP). Although formally statistically
significant (p ¼ 3.2 3 105) after adjusting for the number of
phenotypes and number of pairwise cohort comparisons, we do
not regard this as indicative of substantial cryptic sample overlap
or double counting because (1) the absolute value of the correla-
tion is very low, (2) residual LD exists within the pruned set of
SNPs used to calculate these correlations, and (3) the correlation
we calculated cannot be made completely robust to inflation
because of truly associated SNPs.
Discovery Meta-Analysis Weighting Scheme
For each continuous trait in turn (DBP, MAP, PP, SBP) and for each
single SNP, we meta-analyzed the effect-size estimates and stan-
dard errors obtained from within-study association analyses. We
developed a meta-analysis approach intended to maximize power
in our specific application, namely when combining results
from a mixture of nonascertained studies (BWHHS, GRAPHIC,
PROCARDIS, and WHII) and studies ascertained on the basis of
the phenotypes that are the subject of the association analysis
(from AIBIII, ASCOT, BRIGHT, MDC, NORDIL). Our approach is
motivated by the observation that effect-size estimates from ascer-
tained studies tend to be inflated, relative to effect-size estimates
that would be obtained from a nonascertained population, but
also that, for any given sample size, standard errors for ascertained
studies are inflated relative to those for nonascertained studies
(Figure S6).28 These larger standard errors mean that if a standard
inverse-variance weighting scheme was used, information from
ascertained studies would be inappropriately downweighted. To
avoid this problem, for each ascertained study we estimated an
inflation correction factor (Table S4), which rescales the effect-
size estimates and standard errors, to obtain estimates of the corre-
sponding effect sizes in the populations from which these studies
were ascertained. After rescaling, all studies (ascertained and
nonascertained) are unbiasedly estimating equivalent population
parameters, and inverse-variance weighting of the rescaled
effect-size estimates is therefore asymptotically most powerful.
Intuitively, the effect of rescaling standard errors for ascertained
studies means that those studies then have increased weights in
the meta-analysis of rescaled effect-size estimates.The AmericanFor HTN, for each single SNP we meta-analyzed the effect-size
estimates across studies by using inverse-variance weighting.
Multiple Testing Correction
We estimated the significance threshold that would provide a 5%
overall false-positive rate control (strictly, a 5% family-wise error
rate [FWER]) when five correlated phenotypes (DBP, SBP, MAP,
PP, and HTN) are tested for association with genotypes at the
~50,000 correlated SNPs on the HumanCVD BeadChip with the
spectralmethods of Nyholt29 and Li and Ji.30 The high correlations
between the five phenotypes imply only Meff ¼ 2.7577 effective
tests (Table S5), and the correlations between the ~40,000 poly-
morphic SNPs imply Meff ¼ 21,180 effective tests (Table S6).
Hence, analyzing five phenotypes at ~40,000 polymorphic SNPs
corresponds to a total of Meff ¼ 58,409 effective tests, and we
therefore used a significance threshold of p < 0.05/(58,409) ¼
8.56 3 107 for our discovery analysis.
Follow-Up Analysis
We selected ten independent SNPs at ten distinct loci for follow-up
on the basis of results from our discovery analysis; four SNPs
with p < 8.56 3 107 and six SNPs with suggestive association
(p < 1/58,409 ¼ 1.71 3 105). Where there was no previous or
concurrent report of association with BP phenotypes (at the
NOS3, LSP1/TNNT3, SOX6, NUCB2/KCNJ11/ABCC8, and
CACNA1C loci), we followed up the most significant SNP at
each locus by using a combination of direct genotyping in inde-
pendent samples and look-ups in results from several GWAS data
sets. (We subsequently became aware of a concurrent discovery
of the association at the NOS3 locus.) For the other five loci
(MTHFR-NPPB, AGT, NPR3, HFE and ATP2B1), association with
BP phenotypes had been reported previously4–7,11,12,31 or were
being validated with direct genotyping in a concurrent work.14
For these loci we performed look-ups in results from previously
published meta-analysis (GBPG,6 n ¼ 33,638, except for AGT
where results from GBPG, Cohorts for Heart and Aging Research
in Genomic Epidemiology [CHARGE] and Women’s Genome
Health Study [WGHS], n ¼ 86,588 were previously published12).
We tested each SNP with a single one-tailed test by using the direc-
tion of effect and phenotype with the smallest p value observed in
our discovery meta-analysis. Using a Bonferroni correction for ten
independent tests, we declared successful replication for SNPs with
one-tailed p < 0.05/10 ¼ 0.005. For analysis of combined dis-
covery and replication data, we used a p < 8.56 3 107 threshold
as for our discovery analysis because testing the ten SNPs in
combined analysis is slightly conservative compared to analyzing
all SNPs for association in the full discovery plus follow-up sample
size.32,33
Low-Frequency Variant Analyses
For our study, low-frequency variants were defined as SNPs with
0 < MAF % 0.05 and passing our other QC thresholds used for
meta-analysis (Table S3). To test association with individual low-
frequency SNPs, we simply used our meta-analysis results calcu-
lated as described in Within-Study Association Analyses and
Discovery Meta-Analysis Weighting Scheme and classified accord-
ing to the observed MAF by using the weighted average across
cohorts.
We tested for associations between BP phenotypes and the total
dose of low-frequency alleles, counting alleles at all low-frequency
SNPs within 50 kb of any known transcript for each gene. We
included in our analyses all genes with R20 low-frequency vari-
ants, plus genes near a common variant association discovered
here or previously and genes where rare variant associations
were reported previously.34 We tested the association betweenJournal of Human Genetics 89, 688–700, December 9, 2011 691
the phenotype and total dose (count) of low-frequency alleles
separately for each of our five BP phenotypes by using normal
linear and logistic regression models with ten ancestry PCs as
covariates and then meta-analyzed by using inverse-variance
weighting to combine results from the UK and Irish ancestry
samples and the Nordic ancestry samples.
Identification of Credibly Causal SNPs
We used LD observed in samples resequenced for the 1000
Genomes Project (1000G),35 annotation of encoded protein
sequence changes in known transcripts, and data on transcription
factor binding site (TFBS) peak regions identified by chromatin
immunoprecipitation followed by tag sequencing (ChIP-Seq)
performed by the ENCODE consortium19–24 to determine whether
there were candidate functional SNPs that could potentially be
causally responsible for the observed genotype-phenotype associ-
ations.
Because pairwise LD measures do not directly convey in-
formation about relative strength of association, for candidate
functional SNPs included in our association meta-analysis, we
conducted a model selection analysis. This analysis is motivated
by the knowledge that, even if the true causal variant is a geno-
typed SNP, a different SNP in LD might have a more significant
association and a smaller p value simply by chance. The model
selection analysis does not address the question of whether
a causal relationship exists. Rather, assuming that a sole causal
genetic variant exists at each locus, the analysis discriminates
between a set of mutually exclusive hypotheses about which
genetic variant is the causal one and measures the relative support
for each with the aim of eliminating SNPs that could not credibly
be the sole causal variant at each locus.
Our model selection analysis is different in purpose to condi-
tional analyses, which ask whether two or more SNPs might
jointly be responsible for the observed genotype-phenotype asso-
ciation. Because the models being compared are not nested, clas-
sical model selection criteria such as the likelihood ratio test are
not appropriate. We use a Bayesian model selection criterion, the
Bayes Factor (BF) relative to the SNP with the highest marginal
likelihood at each locus.36 SNPs with BF < 0.05 are not credible
candidates for being the sole causal variant at a locus, and we
use the specific term ‘‘credibly causal’’ to describe SNPs that are
not eliminated by this criterion. This elimination is conservative:
Because marginal likelihoods cannot be calculated for SNPs not
included in our association meta-analysis, BFs are not calculated
for all SNPs, and the BFs that are calculated are upper bounds.
eSNP Analysis and Determination of Coincident Signals
We performed cis-eSNP analyses for loci with SNPs significantly
associated with BP in our analysis of combined discovery and
replication data. For each locus, we used an index SNP that was
most significantly associated with BP or a r2 R 0.9 proxy when
that SNPwas not available in the eSNP data set. At each locus, tran-
script levels for all genes 500 kb on either side of the index SNP
were tested for association with the index SNP genotype in both
eSNP data sets (Table S3). Transcript levels significantly associated
with the index SNP might be mediators of the effect on BP but
might also be artifacts of much stronger transcript associations
at genetic variants that are in only weak LD with an index SNP.
We follow Voight et al.37 and use the term ‘‘coincident’’ when
the data are consistent with the same genetic variant being respon-
sible for the BP association and transcript association signals (and
hence the transcript being a plausible mediator). For each signifi-
cantly associated transcript, we identified the top eSNP (the SNP
with the most significant cis association for the transcript) and692 The American Journal of Human Genetics 89, 688–700, Decembperformed conditional analyses when the index SNP and the top
eSNP were not the same. For the index SNP at SOX6, we also per-
formed a trans-eQTL analysis because functional annotation of
SOX6 suggests its product might regulate the expression of other
genes.Results
For our discovery analysis, we successfully genotyped
25,118 individuals, and 38,069 SNPs passed QC in our
meta-analysis. All five traits analyzed (SBP, DBP, MAP, PP,
and HTN) showed an excess of significant associations at
SNPs with MAF > 5% (Figure 1 and Figures S7 and S8). In
our discovery analyses, four distinct loci (MTHFR-NPPB,
AGT, LSP1/TNNT3, and ATP2B1) had significant associa-
tions at our study-specific significance threshold of p <
8.56 3 107 (Table 1, Table S7, and Figure S8). We targeted
our top ten distinct and independent association signals
for follow-up analysis in a further 59,349 individuals, and
eight of these signals had one-tailed p < 0.05/10 ¼ 0.005
with directions of effect concordant with the discovery
analysis (Table 1, Figure 2, and Table S8). In an analysis of
discovery and follow-up data combined, the eight SNPs
(at the MTHFR-NPPB, AGT, NPR3, HFE, NOS3, LSP1/
TNNT3, SOX6, and ATP2B1 loci) were all associated with
more than one BP trait at our study-specific significance
threshold of p < 8.56 3 107 (Figure 3, Figure S9, and
Table S9). PP and MAP are not simply correlated with SBP
and DBP but are calculated as linear functions of SBP and
DBP, and therefore for these four continuous BP traits
there are only two underlying phenotypic degrees of free-
dom. Hence, all truely associated SNPs must be truely asso-
ciated with at least three (and probably all four) of these BP
traits, and which particular traits were significantly associ-
ated at any given significance threshold conveys little
biologically relevant information beyond that conveyed
by continuous measures of effect size (Figure 3).
Though not providing genome-wide coverage, the
HumanCVD BeadChip specifically targets low-frequency
SNPs17 and so might have an advantage over standard
GWAS platforms to detect association with low-frequency
variants (Figure S10). However, despite our substantial
discovery sample size, we observed no significant associa-
tion with either individual low-frequency SNPs (MAF %
5%) across the whole array (Figure 1 and Figure S7) or
with the total dose of low-frequency alleles in the 93 genes
with the most dense coverage of low-frequency SNPs
(Table S10). We also checked whether CNV-tSNPs were
correlated with our association signals because CNVs are
strong candidate functional alleles, but none of the cred-
ibly causal SNPs at the eight BP loci were found to be
CNV-tSNPs (Table S11).
Several SNPs associatedwith BP previously are genotyped
or tagged by the HumanCVD BeadChip (Table S12). In
our data, we confirmed (at p < 0.05) associations for all
SNPs previously robustly associated with BP in samples of
European ancestry.4,6,7,9,12,14,15er 9, 2011
Figure 1. Quantile-Quantile Plots of Meta-Analysis Results
Each panel shows common (MAF> 5% shown in blue) and low-frequency (MAF% 5% shown in red) SNPs separately. Shaded regions are
99% probability envelopes for no association, which depend on the number of SNPs and hence are different sizes for common and low-
frequency SNPs. The horizontal dashed line indicates our overall study-specific significance threshold p < 8.56 3 107.At the LSP1/TNNT3 locus containing genes for leuko-
cyte-specific protein 1 (LSP1 [MIM 145500]) and troponin
T type 3 (TNNT3 [MIM 600692]), the most significantly
associated SNP was rs661348 in intron 6 of LSP1 in an
~170 kb LDblock (Figure 2).We directly genotyped a nsSNP
(rs621679, LSP1 [p.Ala38Thr (c.112G>A), p.Ala100Thr
(c.298G>A)]) that was not on the HumanCVD BeadChip
and is not in HapMap (CEU [Utah residents with Northern
andWestern European ancestry from the CEPH collection]
release 22), which we identified by using phased haplo-
types from 1000G as being in moderate LD with
rs661348 (r2¼ 0.57; Table S13). Although this nsSNP alone
can explain the observed association and is a candidate on
a priori functional grounds, the statistical evidence for
association was equivocal between rs621679 and
rs661348 (Table S14). At a second locus, SOX6, the most
significantly associated SNP was rs2014408 in intron 3 ofThe Americanthe transcription factor SRY-Box6 (SOX6 [MIM 607257])
in an ~160 kb LD block (Figure 2). This SNP is independent
of a BP-associated SNP (rs381815, r2 ¼ 0.026) reported
previously,7 which is located 537 kb away at the PLEKHA7
locus (Figure S11). The genes at both the LSP1/TNNT3 and
SOX6 loci have no reported connections with BP. At the
SOX6 locus, two SNPs in high LD with rs2014408 (r2 ¼
0.96 with rs1155685 and r2 ¼ 0.87 with rs1701502) might
lie within regions bound by transcription factors (Tables
S13 and S15). If future functional studies can definitively
identify the causal mechanisms underlying the associa-
tions at LSP1/TNNT3 and SOX6 loci, this promises insights
into the basic biology of BP determination.
We also found significant associations at the AGT and
NOS3 loci, consistent with recent reports for AGT.12,31
At these loci, angiotensinogen (AGT [MIM 106150]) and
nitric oxide synthase 3 (NOS3 [MIM 163729]) encodeJournal of Human Genetics 89, 688–700, December 9, 2011 693
Table 1. Results for the Ten Association Signals Targeted for Follow-Up Analysis
Locusa
Index SNP,
Position on
NCBI Build
36 Coordinates
Discovery Data Follow-Up Data
Combined
Discovery and
Follow-Up Data
p Valueb
Coded and
Noncoded
Alleles,
Frequencies
Beta (SE) per
Coded Allele,
p Valueb Phenotype
Coded and
Noncoded
Alleles and
Frequencies
Beta (SE) per
Coded Allele,
One-Tailed
p Valuec
SNPs Followed Up with Direct Genotyping and Look-ups
NOS3 rs3918226,
chr7:150,321,109
T/C 0.08/0.92 þ0.83 (0.18),
p ¼ 2.9 3 106þ
DBP T/C 0.09/0.91 þ0.78 (0.21),
p ¼ 9.5 3 105***
p ¼ 2.2 3 109***
LSP1/TNNT3 rs661348,
chr11:1,861,868
T/C 0.57/0.43 0.65 (0.11),
p ¼ 7.0 3 1010***
MAP T/C 0.55/0.45 0.31 (0.09),
p ¼ 2.0 3 104**
p ¼ 3.0 3 1011***
SOX6 rs2014408,
chr11:16,321,858
T/C 0.21/0.79 þ0.58 (0.13),
p ¼ 9.4 3 106þ
MAP T/C 0.19/0.81 þ0.30 (0.10),
p ¼ 1.2 3 103*
p ¼ 3.5 3 107*
NUCB2/KCNJ11/
ABCC8
rs2074311,
chr11:17,378,436
G/A 0.58/0.42 0.45 (0.10),
p ¼ 2.6 3 106þ
PP G/A 0.58/0.42 0.10 (0.07),
p ¼ 7.6 3 102 NS
p ¼ 6.3 3 105 NS
CACNA1C rs3819526,
chr12:2,306,783
T/C 0.61/0.39 þ0.47 (0.10),
p ¼ 1.8 3 106þ
DBP T/C 0.61/0.39 þ0.10 (0.07),
p ¼ 6.9 3 102 NS
p ¼ 7.5 3 105 NS
SNPs Followed Up with Look-up in GBPG Results Only
MTHFR-NPPB4,6,11 rs4846049,
chr1:11,772,952
T/G 0.33/0.67 0.55 (0.10),
p ¼ 6.7 3 108**
DBP T/G 0.31/0.69 0.34 (0.09),
p ¼ 1.5 3 104**
p ¼ 3.0 3 1010***
AGT12 rs2004776,
chr1:228,915,325
T/C 0.24/0.76 þ0.14 (0.02),
p ¼ 4.3 3 109***
HTN T/C 0.23/0.77 0.08 (0.02)d,
p ¼ 1.9 3 107***d
p ¼ 6.7 3 1014***d
NPR313,38 rs1421811,
chr5:32,750,027
G/C 0.39/0.61 0.67 (0.15),
p ¼ 4.8 3 106þ
SBP G/C 0.37/0.63 0.37 (0.14),
p ¼ 3.5 3 103*
p ¼ 3.4 3 107*
HFE14 rs1799945,
chr6:26,199,158
G/C 0.15/0.85 þ0.62 (0.14),
p ¼ 7.6 3 106þ
DBP G/C 0.14/0.86 þ0.50 (0.12),
p ¼ 2.6 3 105***
p ¼ 2.0 3 109***
ATP2B15 rs11105354,
chr12:88,550,654
G/A 0.16/0.84 0.15 (0.03),
p ¼ 2.4 3 108**
HTN G/A 0.15/0.85 0.12 (0.04),
p ¼ 4.5 3 104**
p ¼ 1.1 3 1010***
The following symbols are used: NS, Not significant at 0.05 level after multiple testing correction; þ, suggestive after multiple testing correction (p < 1/58,409 ¼
1.713 105); *, Significant at 0.05 level after multiple testing correction; **, Significant at 0.01 level after multiple testing correction; ***, Significant at 0.001 level
after multiple testing correction.
a Loci are named according to nearby gene or genes that are strongest functional candidates, based on the position of the index SNP, of correlated nsSNPs, eSNPs,
and ChIP-Seq analyses. Numerical superscripts indicate literature citations for previous reports of genetic associations at these loci where known.
b Adjustment for 58,409 effective tests required.
c Adjustment for ten tests required.
d Including results from Johnson et al.12products with known functional effects on BP (Table 2). At
the AGT locus, we observed multiple SNPs in weak and
modest pairwise LD at our study-specific significance
threshold of p < 8.56 3 107. However, association
analyses conditioning on the most significantly associated
SNP (rs2004776) revealed no significant secondary signals
(Figure S12), consistent with a previous observation that
no multi-SNP haplotype is more significant than this
single SNP.31 In AGT the nsSNP rs699 (p.Met268Thr
[c.803T>C], previously known as p.Met235Thr) is in
moderate LD with rs2004776 (r2 ¼ 0.56) and cannot cred-
ibly be excluded as responsible for the observed association
signal in our data (Table S13). Several other credibly causal
SNPs are located in overlapping peak binding regions for
multiple transcription factors (Tables S13 and S15), sug-
gesting regulation of AGT as an alternative candidate
mechanism. At the NOS3 locus, the most significantly
associated SNP is rs3918226, which is not genotyped on
most standard GWAS arrays, and is not in HapMap CEU
r22, and hence this association could not have been694 The American Journal of Human Genetics 89, 688–700, Decembdiscovered by previous GWAS meta-analyses. This SNP is
located within a region with striking enrichment for
binding by the transcription factor sine oculis homeobox,
Drosophila, homolog of 5 (SIX5 [MIM 600963]; Tables S13
and S15 and Figure S13), which is upstream of the first
coding exon of all common NOS3 transcripts, suggesting
regulation of NOS3 as a candidate functional mechanism.
At the NPR3 and HFE loci, our findings are partly coinci-
dent with those of large GWAS meta-analyses reported
elsewhere. In our data, the most significantly associated
SNP at the NPR3 locus is rs1421811, located in intron 1
of the natriuretic peptide receptor C (NPR3 [MIM
108692]). This SNP is in weak LD with two SNPs reported
elsewhere13,14 (r2 ¼ 0.19 with rs1173771 and r2 ¼ 0.17
with rs1173766). These two SNPs are located 101 kb and
91 kb away from rs1421811, are highly correlated with
each other (r2 ¼ 0.84), and show less significant associa-
tions in our data (Table S12). All of these SNPs are in very
weak LD (r2 < 0.01) with the SNP rs7726475 reported
recently by Zhu et al.38 Thus, our data probably identifyer 9, 2011
Figure 2. Regional Association Plots for Eight SNPs thatWere p< 8.563 107 for at Least One Phenotype in an Analysis of Combined
Discovery and Follow-Up Data
The top of each plot shows local pairwise LD patterns (r2¼ 0 in white; r2¼ 1 in red) and a fine-scale recombination rate map (cyan lines).
The center of each plot shows association results from the discovery analysis only (to maintain an equal sample size for all points) for the
five phenotypes analyzed (DBP in blue, MAP in magenta, PP in green, SBP in red, and HTN in yellow). The bottom of each plot shows
positions of transcripts of known genes.an independent variant at the NPR3 locus affecting BP.
At the HFE locus, our most significantly associated SNP
is rs1799945, which is the same nsSNP (p.His63Asp
[c.187C>G]) in the hemochromatosis gene (HFE [MIM
613609]) reported elsewhere.14 In our data this SNP is an
eSNP, associatedwithHIST1H2BK transcript levels inmono-
cytes (p ¼ 8.5 3 105) and HIST1H2AA transcript levels in
the whole-blood and tissue panel (p ¼ 2.9 3 104; Table
S16). We observed no association between the p.His63AspThe AmericannsSNP and HFE expression levels in monocytes or in the
whole-blood and tissue panel (Table S16). Several other
SNPs in strong LD with HFE p.His63Asp might lie within
regions bound by multiple transcription factors (Tables
S13 and S15), further supporting the possibility of a regula-
tory mechanism at this locus.
Our analyses also identified significant associations at
two previously reported BP loci, ATP2B1 and MTHFR-
NPPB. At the ATP2B1 locus, our most significantlyJournal of Human Genetics 89, 688–700, December 9, 2011 695
Figure 3. Heat Plot Showing Percentage of Phenotypic Variance
Explained in All Available Data for the Eight SNPs
Numeric values are percentage R2 for continuous traits (DBP, SBP,
MAP, PP) and Cox and Snell pseudo-R2 for HTN. Each SNP explains
less than 0.1% of phenotypic variance. Stars indicate significance
levels adjusting for Meff ¼ 58409 tests: *p % 0.05/58,409, **p %
0.01/58,409, ***p% 0.001/58,409.associated SNP is rs11105354, which is perfectly correlated
with previously reported SNPs (Table 2 and Table S12).5,7
At the MTHFR-NPPB locus, the most significantly associ-
ated SNP in our data is rs4846049 in the 30 UTR of 5-10-
methylenetetrahydrofolate reductase (MTHFR [MIM
607093]). We also observed highly significant associations
at two nearby previously reported SNPs4,6 that are in weak
and moderate pairwise LD with rs4846049 (r2 ¼ 0.08 with
rs5068 and r2 ¼ 0.33 with rs17367504), and therefore we
analyzed association with the three SNPs simultaneously.
Each individual SNP was not significantly associated
when added to a multivariate regression model that
included the other two SNPs (Table S17), and it therefore
appears that any two of these three SNPs are sufficient to
jointly tag the causal variant or variants, which remain
to be definitively identified. We identified a credibly causal
nsSNP rs1801131 (MTHFR p.Glu429Ala [c.1286A>C]) in
high LD with rs4846049 (r2 ¼ 0.9). rs4846049 is also an
eSNP, associated with MTHFR (p ¼ 1.91 3 1082) and
CLCN6 (p ¼ 1.6 3 108) transcript levels in the whole-
blood and tissue panel and MTHFR transcript levels in
monocytes (p ¼ 3.1 3 1036 for rs1801131, an r2 ¼ 0.94
proxy; Table S16). A gene regulatory mechanism is further696 The American Journal of Human Genetics 89, 688–700, Decembsupported by the observation that rs4846049, and also the
slightly less significantly associated but still credibly causal
SNP rs3818762, lie within a region with striking enrich-
ment for binding by the signal transducer and activator
of transcription 1 (STAT1 [MIM 600555]; Tables S13
and S15 and Figure S13). Our results and previous studies
indicate the MTHFR-NPPB locus contains multiple
nonindependent SNPs associated with BP, suggesting
potentially several causal variants and several potential
functional mechanisms. Our results highlight the MTHFR
p.Glu429Ala nsSNP as one plausible mechanism and regu-
lation of MTHFR and/or CLCN6 as another.Discussion
In the context of GWAS meta-analyses with larger dis-
covery samples sizes and substantially greater discovery
genotyping effort (n ¼ 34,433 and ~19 billion SNPs geno-
typed;6 n ¼ 29,136 and ~18 billion SNPs genotyped;7 and
n ¼ 69,395 and ~39 billion SNPs genotyped14) than our
discovery sample (n ¼ 25,118 and ~1.3 billion SNPs geno-
typed), it might at first seem surprising that our study
identified BP loci that were not discovered by these
GWAS meta-analyses. However, there was likewise only
modest overlap of the loci that had sufficiently strong
statistical evidence to be claimed as ‘‘discovered’’ by the
two previous GWAS meta-analysis studies with nonover-
lapping samples.16 Similar to other complex disease
phenotypes,39 this observation is consistent with the
hypothesis that the complete genetic architecture of BP
involves a very large number of genetic variants and that
current GWAS or large-scale candidate-gene studies will
discover more-or-less random subsets of this architecture
because their power to detect such variants is low. Our
study can be viewed as an explicit test of a corollary of
this hypothesis, that discovery analyses with samples inde-
pendent of those studied previously will identify BP loci
that have, simply by chance, evaded detection in previous
GWAS with similar or larger sample sizes.
Protein sequence changes encoded by nsSNPs were
specifically targeted in the HumanCVD BeadChip design
because they are strong a priori functional candidates, and
SNPs in transcription factor binding sites can exert
functional effects by modulating transcription factor
binding.40,41 We tested whether such SNPs could be caus-
ally responsible for the observed association signals, explic-
itly taking into account the likelihood of a noncausal SNP
having by chance a smaller p value. Our results are based
on a rigorous analysis and explicit assumptions about the
distribution of the effect sizes (Table S13). The relationship
between our results and those obtained by more ad hoc
approaches (Figures S14 and S15) suggests that the wide-
spread practice of looking only at functional annotation
of SNPs in strong LD (e.g., r2 R 0.8) with index SNPs is
not theoretically well grounded and that previous GWAS
might have overlooked some potential causalmechanisms.er 9, 2011
Table 2. Literature and Functional Annotation for Key Genes at each BP-Associated Locus
Gene Function and References
LSP1 LSP1 encodes leukocyte-specific protein 1, an intracellular F-actin binding protein, primarily expressed in leukocytes and endothelial
cells. Studies of lsp1 knockout mice and other work indicate LSP1 plays a role in signaling, regulating the cytoskeletal architecture
and neutrophil migration.42,43 Recent GWAS meta-analyses have reported polymorphisms in LSP1 to be associated with ulcerative
colitis44 and breast cancer.45
TNNT3 TNNT3 encodes the fast skeletal troponin T protein, also known as Troponin T type 3. Calcium binding to the troponin complex initiates
the process of muscle contraction.46 Mutations in TNNT3 have been found in patients with distal arthrogryposis multiplex congenita
type 2B (DA2B).47
SOX6 SOX6 encodes a transcription factor, which is defined by a conserved high-mobility group DNA binding domain. It is required for
normal development of the central nervous system, chondrogenesis, and maintenance of cardiac and skeletal muscle cells.48
Recent genome-wide association studies show association of polymorphisms in SOX6 with bone mineral density.49
AGT AGTencodes angiotensinogen, which is amember of the renin-angiotensin-aldosterone system (RAAS). Its cleaved products angiotensin
I, angiotensin II and angiotensin III are known regulators of BP and sodium homeostasis.50 There are numerous reports of association of
genetic polymorphisms at the AGT locus associated with hypertension.12,31,51,52
NOS3 NOS3 encodes endothelial nitric oxide synthase, an enzyme that generates nitric oxide (NO). NO plays an important role in the
maintenance of cardiovascular and renal homeostasis.53 Studies of NOS3 knockout mice show heterozygous and homozygous mice
to have increased BP (4 mmHg in þ/ mice and 18 mmHg in / mice) compared to wild type.54
NPR3 NPR3 encodes the natriuretic peptide clearance receptor. The protein acts as a clearance receptor for circulating natriuretic peptides
A, B and C, and also elicits a number of vascular, renal, and endocrine effects directly via its coupling to an inhibitory heterotrimeric
G protein, Gi.55 NPR3 knockout mice show reduced clearance of circulating natriuretic peptides and have lower BP.56 Other
polymorphisms in this gene have recently been reported to be associated with height57 and BP.13,14,38
HFE HFE encodes the hemochromatosis protein, a membrane bound protein involved in regulating iron absorption. The p.His63Asp
(the BP-associated variant) and p.Cys282Tyr nsSNPs in this gene cause the classical autosomal form of hemochromatosis.58 The
p.His63Asp variant has recently been reported to be associated with BP in an independent discovery data set.14
HIST1H2BK HIST1H2BK encodes histone H2B type 1-K. This protein forms a structural part of the nucleosome and functions as a regulator of
chromatin organization and stability.59
HIST1H2AA HIST1H2AA encodes histone H2A type 1-A. This protein forms a structural part of the nucleosome and functions as a regulator of
chromatin organization and stability.59
ATP2B1 ATP2B1 encodes a calcium ATPase, isoform 1, which is a membrane bound protein involved in intracellular calcium homeostasis.60
Polymorphisms in this gene have previously been associated with hypertension.5 The polymorphism associated with BP has recently
been shown to be associated with serum magnesium levels.61
MTHFR MTHFR encodesmethylenetetrahydrofolate reductase, an enzyme involved in homocysteinemetabolism.62 Polymorphisms in this gene
have been reported to be associated with many traits including BP and hypertension.6,8,11,63
CLCN6 CLCN6 encodes chloride transport protein 6, a member of the CLC protein family of Cl- channels and transporters.64 Recent data
indicate CLCN6 functions as anion-proton antiporter, and suggest it might have a dual role in vesicular acidification and chloride
accumulation.65Our discovery and follow-up analyses identified eight
independent genetic variants associated with BP. We attri-
bute the high (80%) success rate to three factors. First, use
of the HumanCVD BeadChip for our discovery analysis
meant that, compared to standard GWAS approaches,
each SNP had higher a priori chances of being truly associ-
ated with BP and also that a less stringent p value threshold
could be used to select SNPs for follow-up because of the
lower multiple testing burden. Second, our discovery
analysis tested five blood pressure phenotypes in parallel,
and we avoided a reduction in power by testing only the
most significantly associated phenotype in our follow-up
analysis. Third, we combined data from population
cohorts and hypertensive case-control cohorts that were
sampled from the extremes of the continuous phenotype
distribution and used a specially developed meta-analysis
weighting scheme that gives appropriately large weights
to the more extreme case-control cohorts that are expected
to yield the greatest information.The AmericanSupplemental Data
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